2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice by Ritschl, Valentin et al.
  707Ritschl V, et al. Ann Rheum Dis 2021;80:707–713. doi:10.1136/annrheumdis-2020-218986
Recommendation
2020 EULAR points to consider for the prevention, 
screening, assessment and management of non- 
adherence to treatment in people with rheumatic and 
musculoskeletal diseases for use in clinical practice
Valentin Ritschl   ,1,2 Tanja A Stamm   ,1,2 Daniel Aletaha   ,3 
Johannes W J Bijlsma   ,4 Peter Böhm   ,5 Razvan Gabriel Dragoi   ,6 
Emma Dures   ,7,8 Fernando Estévez- López   ,9 Laure Gossec   ,10,11 
Annamaria Iagnocco   ,12 Andrea Marques   ,13 Ellen Moholt,14 Michal Nudel,15 
Bart J F van den Bemt   ,16,17 Kirsten Viktil   ,18,19 Marieke Voshaar   ,20 
Annette de Thurah   ,21,22 Loreto Carmona   23
To cite: Ritschl V, 
Stamm TA, Aletaha D, 
et al. Ann Rheum Dis 
2021;80:707–713.
Handling editor Désirée van 
der Heijde
 ► Additional material is 
published online only. To view, 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
annrheumdis- 2020- 218986).
For numbered affiliations see 
end of article.
Correspondence to
Tanja A Stamm, Section for 
Outcomes Research, Medical 
University of Vienna, Wien, 1090 
Wien, Austria;  
 tanja. stamm@ meduniwien. ac. at
Received 27 August 2020
Revised 23 October 2020
Accepted 26 October 2020
Published Online First 
18 December 2020
© Author(s) (or their 
employer(s)) 2021. No 
commercial re- use. See rights 
and permissions. Published 
by BMJ.
ABSTRACT
Background Non- adherence to treatment could 
preclude reaching an optimal outcome. Thirty to 80% of 
patients with rheumatic and musculoskeletal diseases 
(RMDs) do not adhere to the agreed treatment.
Objectives The objective was to establish points to 
consider (PtCs) for the prevention, screening, assessment 
and management of non- adherence to (non- )
pharmacological treatments in people with RMDs.
Methods An EULAR task force (TF) was established, 
and the EULAR standardised operating procedures for 
the development of PtCs were followed. The TF included 
healthcare providers (HCPs), comprising rheumatologists, 
nurses, pharmacists, psychologists, physiotherapists, 
occupational therapists and patient- representatives 
from 12 European countries. A review of systematic 
reviews was conducted in advance to support the TF in 
formulating the PtCs. The level of agreement among the 
TF was established by anonymous online voting.
Results Four overarching principles and nine PtCs 
were formulated. The PtCs reflect the phases of action 
on non- adherence. HCPs should assess and discuss 
adherence with patients on a regular basis and support 
patients to treatment adherence. As adherence is an 
agreed behaviour, the treatment has to be tailored to the 
patients’ needs. The level of agreement ranged from 9.5 
to 9.9 out of 10.
Conclusions These PtCs can help HCPs to support 
people with RMDs to be more adherent to the agreed 
treatment plan. The basic scheme being prevent non- 
adherence by bonding with the patient and building 
trust, overcoming structural barriers, assessing in a 
blame- free environment and tailoring the solution to the 
problem.
INTRODUCTION
Thirty to 80% of people with rheumatic and muscu-
loskeletal diseases (RMDs) do not follow the recom-
mended treatment plan.1–3 Non- adherence equally 
affect medication, non- pharmacological interven-
tions and keeping follow- up appointments and are 
associated with worse outcomes, increased risk of 
cardiovascular disease, decreased functioning and 
loss of health- related quality of life.1–7 Strategies to 
reduce non- adherence are thus essential to achieve 
an optimal outcome.4–6
The problem of non- adherence is addressed in 
some EULAR recommendations on the manage-
ment of specific health conditions or in the role of 
professionals, but none specifies interventions in or 
actual directions on how to improve non- adherent 
behaviour.8–11 All these recommendations focus on 
specific aspects of non- adherence and do not cover 
the multifaceted nature of this phenomenon, such 
as its detection or assessment.
Although general recommendations are lacking, 
a large number of studies have tested various 
interventions targeting non- adherence, including 
screening and assessment of non- adherence,1 provi-
sion of equitable and coordinated access to treat-
ment through, for example, flexibility in scheduling 
or financial resources according to the respective 
health system,12 integration of patients in treatment 
decisions,12 enhancement of patients’ autonomy,13 
stratification and individualisation of interventions 
based on the needs and preferences of patients 
including psychosocial markers,8 9 information and 
education,10–13 systems to remind patients about 
appointments, intake of medication and exercises 
whenever necessary,14 compatibility of treatment 
interventions to the daily routines of patients,9 13 
and offer opportunities to get in touch with other 
individuals with similar health conditions or other 
social support.12 13 Interventions are delivered by 
rheumatologists, other medical specialists, general 
practitioners or health professionals in rheuma-
tology (HPRs) (ie, nurses, pharmacists, physiother-
apists, occupational therapists and psychologists) in 
close collaboration with each other in primary and 
secondary care settings.
The objective of the present work is to estab-
lish points to consider (PtCs) for the prevention, 
screening, assessment and management of non- 
adherence in people with RMDs for use in daily 
clinical practice.
The users of these PtCs are intended to be rheu-
matologists and HPRs (together will be referred as 
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healthcare providers or HCPs), patients and caregivers, regu-
lators, trainers and others, at the individual or organisational 
level (eg, patient organisations, pharmaceutical and/or insurance 
companies). Regarding their scope, these PtCs are applicable to 
all RMDs, except those with an acute or subacute course (eg, 
some viral arthritis), as longer duration of diseases increase the 
chances of non- adherence.4 In addition, the scope of the PtCs 
does not include children and adolescents, as their non- adherent 
behaviour differs from that of adults, mainly on its great reli-
ance on social support of caregivers.15 We acknowledge that 
different RMDs may have specific problems—for example, non- 
symptomatic conditions, such as osteoporosis, pose additional 
challenges to motivate a patient to follow a long- term prescrip-
tion (prescription in this context refers to any instruction (mostly 
written) from a physician or health professional in rheumatology 
stating the form, dosage and kind of treatment, including but not 
limited to medications, exercises, diets and follow- up appoint-
ments); however, non- adherence affects them all, and only very 
exceptionally a PtC for an RMD might not apply to another.
In addition, these PtCs only refer to non- adherence to pharma-
cological or non- pharmacological treatments that are prescribed 
or recommended. They are not including non- adherence to 
lifestyle changes, such as diet, weight loss and smoking or to 
visit schedules. Regarding medication, the task force decided 
that symptomatic medicines may not be the specific objective of 
these PtCs, and that non- pharmacological treatments should be 
restricted to exercises and medical devices (eg, splints). Exercises 
may be defined as a type of physical activity that is planned, 
structured and purposeful.16 17
Finally, in the context of these PtCs and following the defi-
nition of the WHO, non- adherence is defined as the extent to 
which a person’s behaviour does not correspond with the agreed 
prescription, of pharmacological or non- pharmacological treat-
ments, by an HCP.4 Besides being intentional or non- intentional, 
non- adherence (1) may occur at the start of treatment (initial 
non- acceptance), and so the patient never collects the prescrip-
tion, or does not sign up to exercises, and hence does not follow 
any of the prescription; (2) may be a result of a poor execution, 
either by taking an incorrect dose, taking the drug at a wrong 
time or by decreasing or increasing the frequency of doses (or 
their equivalents in exercises or the use of medical devices) or 
(3) may be due to discontinuation of the treatment at any time 
during the treatment course.1
METHODS
These PtCs were developed according to the consensus process 
suggested by the EULAR Standard Operating Procedures.18 An 
international expert task force was established by a steering 
committee (LC, VR, AdT and TAS), and included people with 
RMDs (n=2), EMEUNET members (n=3 (AM, RGD and 
VR)), and representatives from relevant HCP groups: nurses 
(n=3), occupational therapists (n=2), psychologists (n=3), 
physiotherapists (n=1), pharmacists (n=2) and rheumatologists 
(n=6), all of whom had various levels of expertise in the field 
of non- adherence and came from a broad geographical distri-
bution across Europe. A systematic review (SR) of reviews and 
meta- analysis on existing strategies to prevent or mitigate non- 
adherence, supervised by the methodologist and the convenors, 
was presented at a first task force meeting (the SR is subject of a 
separate publication19). In this meeting, the scope, users, structure 
of the document and overarching principles were established by 
nominal group technique, as well as additional clinical questions 
to be addressed by SR. These clinical questions were converted 
into Population Intervention Comparison Outcome questions by 
the convenors (LC and VR), methodologist (AdT) and research 
fellows (VR and JBNT), and the search strategies developed, by 
an experienced Librarian, in Medline, CINAHL, web of science, 
science direct and the Cochrane Database of SR. The quality of 
the selected reviews was assessed using ‘A MeaSurement Tool 
to Assess systematic Reviews’ (available at https:// amstar. ca/). 
The quality and risk of bias of the original studies were obtained 
directly from the published reviews (ie, Cochranes Risk of Bias 
tool20 for intervention studies and QUADAS-221 for assess-
ment studies). Because of the high heterogeneity, the evidence 
was synthesised qualitatively. In a second meeting of the task 
force, the results of the SR were discussed and the PtCs were 
formulated. Data from the SR were categorised according to 
the Oxford system for levels of evidence,22 and statements were 
voted and discussed using a three round Delphi technique. Level 
of agreement (LoA)/voting was scored anonymously ( www. sli. 
do) on a numerical rating scale ranging from zero (completely 
disagree) to 10 (completely agree). The first two Delphi rounds 
were performed during the second task force meeting. Agree-
ment in the Delphi was defined as >80% of experts within the 
task force voting in favour (nine or 10) or against (one or two) 
an item. Items with agreement against were excluded from the 
list. Items with agreement in favour were maintained without 
further voting, unless reformulation was proposed. All inter-
mediate items and those that needed reformulation were voted 
in a second round. Finally, in the third Delphi round (done by 
electronic communication ( www. surveymonkey. de)), task force 
members were asked to give their final rating on every point to 
consider. All members of the task force were asked to respond 
during each round.
RESULTS
The results of the taskforce efforts are divided into four over-
arching principles and nine PtCs. The difference, in absence of 
strong evidence, is that overarching principles are not sugges-
tions on what to do, but more principles to understand why and 
how the following points are formulated. They are explained 
and justified in detail below and presented in table 1 with the 
accompanying level of evidence (LoE), grade of recommenda-
tion (GR) and LoA.22
Overarching principles
Overarching principle A: adherence impacts the outcomes of people 
with RMDs
In RMDs, non- adherence has been associated with worse disease 
severity, increased pain and fatigue, higher rates of depression, 
lower function and a decrease in quality of life and physical 
activity.19
Overarching principle B: shared decision making is key, since 
adherence is a behaviour following an agreed prescription
Ideally, patients and their HCPs should agree on the recom-
mended treatment, including duration, dosage and frequency of 
medication intake, or exercises or device use over a period of 
time. To make an informed decision, patients need to under-
stand their choices (ie, shared decision making, or SDM). The 
SDM process has been defined as ‘an approach where HCPs and 
patients share the best available evidence when faced with the 
task of making decisions, and where patients are supported to 
consider options, to achieve informed preferences’.23 During 
the SDM process, mutual expectations in terms of efficacy, 
safety and monitoring should be discussed, as well as fears and 









is: first published as 10.1136/annrheum






709Ritschl V, et al. Ann Rheum Dis 2021;80:707–713. doi:10.1136/annrheumdis-2020-218986
Recommendation
necessities about the specific treatment. The patient should be 
informed about the need to be adherent and how adherence will 
be evaluated. Agreement is part of the definition of adherence in 
the sense that if the patient did not agree to start with, it could 
not be considered non- adherence. Although, SDM is ambitious 
in systems with time constraints and low availability of profes-
sionals, it cannot be overlooked if we want to action at all on 
non- adherence.
Overarching principle C: adherence is influenced by multiple factors
Patients may have comorbidities, multiple treatments, circum-
stances, cognitions and preferences that need to be taken into 
account, when addressing non- adherence. Health systems are 
complex and, in each setting, different HCPs may have different 
roles. These PtCs have an integrative approach that goes beyond 
the clinical encounter, as they stress that all, HCPs and patients, 
are involved in the care of patients.
Overarching principle D: adherence is a dynamic process that 
requires continuous evaluation
Patients’ beliefs and fears about prescribed treatments, as well 
as behaviours, are influenced by experience and by external and 
internal determinants, for example, depression, other comorbid-
ities, side effects, lack of efficacy or life changes that pose logistic 
hurdles. We cannot assume that a person will continue to be 
adherent or non- adherent to any given treatment, and that this 
will be maintained and stable across prescriptions.
Points to consider
PtC 1: all HCPs involved in the management of people with RMDs 
should take responsibility for promoting adherence
Effective interventions to reduce non- adherence in RMDs were 
reviewed by our group, and we confirmed that HCP, both physi-
cians—namely, rheumatologists, GP and orthopaedic surgeons—
and HPRs—such as nurses, physiotherapists, occupational 
therapists, psychologists, exercise physiologists, patient educa-
tors and pharmacists—were involved in the delivery of these 
interventions.19 Nieuwlaat et al underscore in their Cochrane 
review that nurses, pharmacists and therapists are increasingly 
becoming part of delivering interventions that target non- 
adherent behaviour in people with RMDs.24 This PtC gives 
responsibility to the full care team. It highlights both the rele-
vant role of these HPRs and also both the need to acknowledge 
their efforts, and to coordinate teams beyond the rheumatology 
clinic. Training in specific interventions—for example, motiva-
tional interview or communication skills—may also be behind 
effective or non- effective interventions.25 Very importantly, the 
HCPs should be involved and should be trained as well.
PtC 2: effective patient-health professional communication should 
be applied to enhance adherence
An overview of SR on strategies proven effective to reduce non- 
adherence to medication and prescribed exercises found that 
effective communication was part of most multifaceted interven-
tions proven successful. Unfortunately, the content and nature 
of effective communication is not well detailed.19 Despite the 
absence of consensus on a definition of effective communication, 
its components—namely, empathy, open questions or bilateral 
feedback, among others—were discussed and detailed by the 
task force (see online supplemental table S3).25–27 Very impor-
tantly, as effective communication helps build trust with the 
patient and ensures a proper transmission of information about 
the condition and treatment,25–28 it should be in place before the 
point at which the prescription is discussed.
PtC 3: barriers and facilitators of adherence of a specific patient to a 
specific prescription should be appropriately evaluated
Many different factors determining non- adherent behaviour 
in people with RMDs have been identified in many studies, 
covering various domains. The WHO generated a framework by 
which these factors were classified into five different domains: 
(i) patient- related, (ii) condition- related, (iii) therapy- related, 
(ív) the socioeconomic context and (v) the healthcare system.4 
Our overview of SR of qualitative studies demonstrated that the 
list of barriers and facilitators is extensive, with many factors not 
being modifiable, and none of them being a sole predictor of 
non- adherence.19
Table 1 Overarching principles and points to consider for the prevention, screening, assessment and management of non- adherence in people 
with RMDs for use in the daily clinical practice
Adherence is defined as the extent to which a person’s behaviour corresponds with the agreed prescription*4
Overarching principles LoA
A Adherence impacts the outcomes of people with RMDs. 98.6
B Shared decision making is key, since adherence is a behaviour following an agreed prescription. 95.8
C Adherence is influenced by multiple factors. 97.5
D Adherence is a dynamic process that requires continuous evaluation. 96.2
Points to consider LoE GR LoA
1 All HCPs involved in the management of people with RMDs should take responsibility for promoting adherence. 5 D 98.6
2 Effective patient- health professional communication should be applied to enhance adherence. 5 D 99.4
3 Barriers and facilitators of adherence of a specific patient to a specific prescription should be appropriately evaluated. 5 D 95.2
4 Patient education should be provided for people with RMDs as an integral part of standard care. 1A A 95.9
5 Care should be tailored to patient preferences and goals to enhance adherence. 5 D 98.4
6 Adherence should be discussed regularly based on open questions and particularly when disease is not well controlled. 5 D 98.9
7 The HCP should explore which factors might negatively influence adherence, including: opportunity (eg, availability or cost), capability (eg, memory 
problems), motivation (eg, concerns).
5 D 93.8
8 Together with the patient, the HCP should tailor the approach to overcome individual barriers to adherence, for example, simplifying the regimen, using 
reminders, providing education, discussing the patient’s beliefs on treatments.
5 D 97.9
9 When specific expertise or interventions for adherence are needed, they should be made available to patients. 5 D 97.7
*Prescription in this context refers to any instruction (mostly written) from a physician or health professional in rheumatology stating the form, dosage and kind of treatment, including but not limited to medications, 
exercises, diets and follow- up appointments.
GR, grade of recommendation20 ; HCP, healthcare providers; LoA, Level of agreement of task force members on a numeric rating scale from 0 (no agreement) to 10 (perfect agreement); LoE, level of evidence; RMDs, 
rheumatic and musculoskeletal diseases.
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Some factors change with time and can appear either to be a 
cause, or a consequence, of patient non- adherence (eg, depres-
sion can lead to less motivation to adhere, but it can also be a 
consequence of disease activity due to non- adherence). Barriers 
to adherence are considered complex and multi- faceted and 
non- adherence should never be perceived as patients’ fault only 
(eg, the hospital pharmacy was not open the only day a patient 
could take off from work that month, or the patient’s skills for 
self- injection are very limited). Based on the overview SR,19 we 
have produced a checklist of factors related to non- adherence, 
which could help HCPs to identify barriers to adherence at the 
individual level (see online supplemental table S1).
PtC 4: patient education should be provided for people with RMDs 
as an integral part of standard care
Most interventions with proven effectiveness in non- adherence 
include components of patient education,19 namely provision 
of knowledge or information, self- management programmes, 
cognitive behavioural interventions, mindfulness, stress manage-
ment, individual consultations, sharing experiences among 
patients, motivational discussions, exercise counselling, lifestyle 
change interventions and self- help courses. With this PtC, the 
task force wants to emphasise that ‘all people with RMDs should 
have access to and be offered patient education throughout the 
course of their disease including as a minimum; at diagnosis, 
at pharmacological treatment change and when required by the 
patient’s physical or psychological condition’.11
Of course, we cannot overwhelm the patient at diagnosis or 
treatment start with information, but studies agree in that patient 
education, either direct or supported via websites,29 30 brochures, 
SMS24 25 or e- health may reduce non- adherent behaviour. In 
order to be effective, education/information should include 
information about drugs,31 32 disease process,31 32 physical exer-
cises,31 joint protection,31 33 pain control,31 33 coping strategies31 
and lifestyle changes.32 33 Delivery formats can include verbally 
(face to face31 or by telephone34), written (as leaflets31 or using 
test messages29 30) and visualised in charts35 (see online supple-
mental table S2).
PtC 5: care should be tailored to patient preferences and goals to 
enhance adherence
As already mentioned, the list of potential factors that can influ-
ence non- adherence to treatment is extensive and challenging to 
address. However, building a trust and a sound patient–HCPs 
relationship will prepare the scene for a responsible and blame- 
free framework that will reduce non- adherence in the long 
term.2 28 This tailored care has a maximum exponent during the 
SDM process, when options and patient preferences are the basis 
for an agreement to be treated and monitored.23
PtC 6: adherence should be discussed regularly based on open 
questions and particularly when disease is not well controlled
As adherence changes with time, the task force could not specify 
a best moment to assess non- adherence. Finally, we suggest that 
non- adherence should be assessed in a continuum. The task 
force discussed the opportunity to discuss non- adherence when 
the disease is not well controlled but specifically agreed to high-
light the need for regularity. Regularly in this context would be, 
at a minimum, once per year.
Some experts within the TF argued to use validated measures 
of non- adherence, for instance, by the Medication Event Moni-
toring System, the level/dose ratio or the medication possession 
ratio.36 The reality is that the non- adherence construct has many 
grey areas and more than 200 ways to measure non- adherence 
to medication exist.37 The TF undertook an SR of instruments 
to screen non- adherence to medication and exercises in people 
with RMDs, including but not limited to validated questions, 
questionnaires, assessment and others (eg, pill counts, worn 
splint), without identifying a single measure that was clearly 
superior, neither for medication nor for exercises.19
In practical terms, whether non- adherence is a problem or 
not, it should be discussed through open conversation with the 
patient. The ‘some people’ approach may facilitate the generation 
of a safe space for more elaborated questions and answers (‘We 
know it can be difficult, everybody has some problems, could 
you tell me what problems you encountered when taking your 
medication?’ or ‘Could you show me how you actually wear the 
splint? How do you actually perform the exercises?’).28 Other 
forms of screening, like questionnaires, looking at pharmacy 
indicators, drug levels or wearables can be used, always tailored 
to patient preferences and goals to reduce non- adherence, but a 
single measure without the open discussion is not recommended.
PtC 7: the HCP should explore which factors might negatively 
influence adherence, including opportunity (eg, availability or cost), 
capability (eg, memory problems) or motivation (eg, concerns)
This PtC adds a method or systematic approach to explore 
barriers to adherent behaviour. We used the Capability, 
Opportunity and Motivation model of Behaviour (COM- B) 
as framework to explore patient’s drivers for non- adherence 
and as instrument to identify possible targets for reducing non- 
adherence.38 The model acknowledges that behaviour is part 
of an interacting, dynamic system involving these components 
to determine a person’s non- adherence. The problems that are 
easiest to address are those of practical nature—for example, 
unavailability at local pharmacy, pharmacy open hours, interfer-
ence with occupation —and thus they should be the first ones 
explored. Next would be knowledge or capability related, for 
example, the patient does not really understand the duration of 
treatment, what to do in case of missing dose, or how to inject. 
These can be explored by asking the patient, with some level of 
detail, how she or he actually takes the medication or, in the case 
of exercises, how he or she performs the exercises. Regardless of 
problems in these previous areas, the motivation to adhere, or 
intention, has to be explored. This is usually explored in terms 
of needs and concerns.1
PtC 8: together with the patient, the HCP should tailor the approach 
to overcome individual barriers to adherence, for example, 
simplifying the regimen, using reminders, providing education, 
discussing the patient’s beliefs on treatments
Based on the reasons for non- adherence, the solutions must be 
tailored to tackle the specific problems. There is not general 
recipe or ‘one size fits all’ as how to do this and solutions to tackle 
non- adherence are plenty. The two steps of a tailored approach 
would be (1) to identify the reasons of non- adherence, including 
the assessment of problems, as well as low health literacy or skills, 
and (2) to focus on the specific problems, modulating the inter-
vention to the individual (eg, a patient clearly needs a reminder 
but does not have a smartphone, we should recommend the use 
of pill boxes with timers). Some randomised controlled trials 
that specifically named their strategies as ‘tailored’ showed posi-
tive results.32 34 39–41 Many include revising treatment schemes to 
make them as convenient and easy to follow as possible.
Besides patient education strategies, already highlighted, 
there are simple things that can be done, like advising on cueing 
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behaviours (eg, pairing medication taking with an established 
behaviour, such as brushing teeth),42 monitoring (eg, using 
a calendar or a diary to track medication taking),42 including 
the family and close ones in the intervention,42 review plans/
strategies and give feedback (including positive reinforcement) 
and answers.42 Individualising the prescription and regimen 
according to the preferences and goals of the patient has been 
proven effective.43 In the case of exercises, it has been suggested 
to split treatment visits,44 increase proxy efficacy (ie, patients’ 
confidence in the therapist’s ability to function effectively on 
his/her behalf; this can be done by showing that the therapist 
competency really aids achieving goals)45 and discuss barriers 
and facilitators of exercises with the patient,46 encouraging him/
her to plan own treatment regimens, discussing intentions and 
helping recasting unrealistic plans,46 individualising physical 
activity advice,40 tailor graded exercise programme,47 training 
in the proper execution of physical exercises46 and providing 
visual media of the prescribed exercises and explanatory written 
information.48 A list of practical things is shown in the online 
supplemental table S2.
PtC 9: when specific expertise or interventions for adherence are 
needed, they should be made available to patients
Some interventions, especially those related to avoid intentional 
non- adherence may need specialised skills, such as motivational 
interviewing.24 If the care team includes a psychologist, she or he 
should be ideally involved, either in the management of the indi-
vidual patients or as trainer or consultant for the team members. 
Other skills, such as being able to deliver effective communica-
tion, are insufficiently incorporated in most teams.
DISCUSSION
The topic of non- adherence is of utmost importance and yet 
not adequately addressed in rheumatology. Non- adherence 
both results in poorer outcomes and also in increased resource 
use and medical costs.49 Non- adherence varies across RMDs, 
being critical in gout,50 51 and osteoporosis,52 but also in rheu-
matoid arthritis, where it even vary across medication.49 The 
work of this multidisciplinary taskforce has highlighted both the 
complexity and a possible practical approach to non- adherence 
to prescribed treatments in RMDs.
The WHO definition of adherence does not easily translate 
into operational terms, as it relates to a behaviour.16 Non- 
adherence can take many different forms: the patient could actu-
ally be overdosing the medication, the exercises or the use of 
devices, or not using it as prescribed (eg, misapplying medication 
or exercises, or using splints ineffectively). The complexity and 
difficulty of identifying factors accurately and predicting medi-
cation non- adherence has led to the development of cognitive 
models to better explain this complex phenomenon.1 12 53 These 
models take into account areas such as illness beliefs, expec-
tations, barriers and intentions, and have become the basis 
of measurement instruments.36 In practical terms, and in the 
context of a frank discussion, we should ask the patient about 
his or her beliefs and concerns about treatments, as these are 
universally present in patients on long- term treatments.54 In 
this line, Foot et al found a moderate effect of pharmacological 
treatment necessity in rheumatoid arthritis and systemic scle-
rosis—both being the RMDs with largest ‘need’ belief of treat-
ment—and lowest in osteoporosis, while they found a strong 
negative association between concerns about adverse effects of 
taking medicines and non- adherence in rheumatoid arthritis and 
in osteoporosis and moderate in systemic sclerosis.55 Patients will 
always weigh up necessity and concern, and therefore we have a 
‘window of opportunity’ for patient education and counselling.
Patient- centeredness and shared decisions are key elements in 
relation to (non- )adherence. If perspectives and preferences of 
patients are not adequately taken into account in medical deci-
sions, non- adherence might get a paternalistic connation. Instead 
the HCP ‘telling’ the patient what to do and the patient needing 
to follow this advice, a common patient- centric perspective 
should be established, and patients should be encouraged to take 
active role in the subsequent decision. However, we acknowl-
edge, that it is not possible for HCPs to assess or be certain that 
a patient has agreed to the proposed treatment plan, especially 
because some patients may give socially desirable answers (for 
fear of disappointing the HCPs). Therefore, adherence should 
be discussed regularly, and the patients must be given assurance 
that they can be honest, because it is their right not to take the 
treatment as prescribed. However, the patients should also be 
encouraged to tell the HCPs about not taking the treatment as 
only with mutual trust, optimal can take place.
The aim of our taskforce was to be as practical as possible. 
Other groups have already issued recommendations to reduce 
non- adherence in RMDs,56 but they dealt specifically with medi-
cation and rheumatoid arthritis, and we wanted to be broader. 
A practical local initiative designed a model for prescription to 
tackle non- adherence,57 and in a very practical paper, Rashid 
et al synthesise the implications of qualitative research in the 
field of non- adherence into the following 11 statements: (1) 
individualise care plan, (2) address practical barriers for the 
individual, (3) adopt a patient- centred approach, (4) increase 
HCPs involvement, (5) ensure long- term follow- up, (6) promote 
self- management, (7) increase family or carer involvement, (8) 
improve patient education, (9) address system barriers, (10) 
increase access to non- prescribing HCPs and (11) improve staff 
training.58 Many of these suggestions reflect our views and 
conclusions.
Exercises are a pillar in the treatment of most RMDs and non- 
adherence may be even larger than to medication. We realise that 
both the definition of adherence and most of the literature deal 
with non- adherence to medication, and thus will not entirely 
apply to exercises or to other prescribed treatments, such as use 
of splints. However, due to the generic nature of the PtCs, we 
assume that our results can equally be applied to any treatment 
the patient is receiving and thus will cover exercises as well.
Two aspects differ from the initial plans of this taskforce. 
First, prevention was not initially included as an objective of 
the taskforce; however, it soon became clear that prevention is 
the ultimate solution to avoid non- adherence, and strategies to 
achieve it will probably overlap with those of an optimal SDM 
process. Second, in the proposal approved by the EULAR exec-
utive, non- adherence to visits and to diet, and not only to medi-
cation or exercises, were initially included. However, the task 
force thought that visits and diet were too complex to measure, 
and would overlap with other initiatives, and left them out of the 
scope and the research agenda.
Finally, regarding the implementation of these PtCs, the task 
force wanted to stress, on one hand the need to adopt a truly 
patient- centred approach and, on the other, the need to make 
system changes. Several PtCs involve the patient as main stake-
holder in the issue of non- adherence. Nothing can be done in 
terms of non- adherence without the help of the one who agrees, 
or not, to follow the treatment or exercises as prescribed. To 
engage him or her, we will need to attain basic effective commu-
nication skills and make SDM a reality. The consequences will be 
a better outcome and higher odds of adequate self- management. 
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Similarly, if we do not evaluate periodically non- adherence at an 
organisational level, and address system barriers, many of which 
are modifiable, including improved staff training, we will not be 
able to make effective changes, or measure the impact of imple-
mented strategies. There is enough information to support better 
use of existing resources and treatments, this include reducing 
non- adherence.
In summary, these PtCs can help HCPs to support people with 
RMDs to adhere to the agreed treatment plan, the basic scheme 
being minimise non- adherence by bonding with the patient and 
building trust, and by overcoming structural barriers, assess in a 
blame- free environment and tailor the solution to the problem.
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